ea0081p415 | Pituitary and Neuroendocrinology | ECE2022
Johannsson Gudmundur
, MK Biller Beverly
, Fukuoka Hidenori
, Ho Ken
, Hojby Rasmussen Michael
, Nedjatian Navid
, Svaerke Claus
, CJ Yuen Kevin
, Takahashi Yutaka
Somapacitan is a once-weekly, long-acting growth hormone (GH) derivative approved for the treatment of adult GH deficiency (AGHD). Our objective was to evaluate the effects of somapacitan on glucose metabolism compared with daily GH or placebo in patients with AGHD using data from three previously published phase 3 trials: REAL 1 (NCT02229851), REAL 2 (NCT02382939) and REAL Japan (NCT03075644). REAL 1 was a randomised, placebo-controlled (double-blind) and active-controlled (o...